https://mindmedicinelaw.com/briefing/mdma-therapy-risk-factors-in-u-s-veterans-with-ptsd-20260805-29674The Psychedelic Journalen2026-08-06T22:06:01.384533+00:00MDMA Therapy Risk Factors in U.S. Veterans with PTSDMDMA-assisted therapy, veterans, PTSD, contraindications, risk factors, clinical practice, policy implications, psychotherapy, public health, neurosciencehttps://mindmedicinelaw.com/briefing/innovative-therapies-for-treatment-resistant-depression-20260805-29696The Psychedelic Journalen2026-08-06T22:05:53.587171+00:00Innovative Therapies for Treatment-Resistant Depressiontreatment-resistant depression, ketamine, esketamine, antidepressant strategies, neurotransmission, individualized treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-als-treatment-mechanisms-and-implications-20260805-29686The Psychedelic Journalen2026-08-06T22:05:46.456776+00:00Ketamine's Role in ALS Treatment: Mechanisms and Implicationsketamine, ALS treatment, sigma-1 receptor, neuroplasticity, mitochondrial function, neurodegenerative diseases, clinical trials, FDA, therapeutic strategies, pharmacological mechanismshttps://mindmedicinelaw.com/briefing/eeg-study-links-ubes-to-brain-complexity-changes-20260804-29655The Psychedelic Journalen2026-08-07T15:06:13.883893+00:00EEG Study Links UBEs to Brain Complexity Changesunusual bodily experiences, EEG study, brain complexity, cortical hierarchy, psychedelic states, depersonalization, body-image disorders, neural dynamics, consciousness research, mental health treatmenthttps://mindmedicinelaw.com/briefing/machine-learning-and-fmri-predict-ssri-response-in-mdd-20260804-29697The Psychedelic Journalen2026-08-06T22:06:19.032641+00:00Machine Learning and fMRI Predict SSRI Response in MDDmachine learning, fMRI, SSRI, major depressive disorder, personalized treatment, neuroimaging, clinical trials, predictive modeling, mental health, pharmacotherapyhttps://mindmedicinelaw.com/briefing/exercise-modulates-depression-circuits-implications-for-therapy-20260804-29698The Psychedelic Journalen2026-08-06T22:06:10.331039+00:00Exercise Modulates Depression Circuits: Implications for Therapyexercise and depression, lateral habenula, NMHA model, non-pharmacological therapy, neuroplasticity, clinical trials in depression, mental health researchhttps://mindmedicinelaw.com/briefing/impact-of-female-sex-hormones-on-psychedelic-efficacy-20260804-29654The Psychedelic Journalen2026-08-06T22:05:36.376681+00:00Impact of Female Sex Hormones on Psychedelic Efficacypsychedelics, female sex hormones, mental health, pharmacokinetics, pharmacodynamics, clinical trials, hormonal fluctuations, 5-HT2A receptor, women's health, psychiatric disordershttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-salivary-glands-new-research-insights-20260804-29256The Psychedelic Journalen2026-08-05T22:04:48.654577+00:00Ketamine's Impact on Salivary Glands: New Research Insightsketamine, salivary glands, redox balance, inflammatory homeostasis, recreational drug use, clinical guidelines, public health, biochemical impacts, therapeutic use, safety profilehttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-modulate-motivation-20260803-29375The Psychedelic Journalen2026-08-06T15:06:23.492383+00:00GABAergic Cells in Zona Incerta Modulate MotivationGABAergic cells, zona incerta, motivation modulation, mental health treatments, neuroscience research, behavioral tasks, chemogenetics, fiber photometry, treatment-resistant deficitshttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-new-targets-for-motivation-20260803-29374The Psychedelic Journalen2026-08-06T15:06:14.600819+00:00GABAergic Cells in Zona Incerta: New Targets for MotivationGABAergic cells, zona incerta, motivation modulation, treatment-resistant disorders, neuroanatomical targets, chemogenetics, fiber photometry, motivational deficits, neuroscience research, therapeutic strategieshttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-new-targets-for-motivation-20260803-29371The Psychedelic Journalen2026-08-06T15:06:04.366103+00:00GABAergic Cells in Zona Incerta: New Targets for MotivationGABAergic cells, zona incerta, motivation modulation, treatment-resistant deficits, chemogenetics, neurobiological mechanismshttps://mindmedicinelaw.com/briefing/oneness-experience-scale-a-new-tool-for-mindfulness-research-20260803-29331The Psychedelic Journalen2026-08-06T15:05:45.242975+00:00Oneness Experience Scale: A New Tool for Mindfulness Researchoneness experience scale, mindfulness research, nondual awareness, spiritual practices, psychometric evaluation, mental health, therapeutic practices, construct validity, well-being, psychedelic researchhttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-new-insights-into-motivation-20260803-29370The Psychedelic Journalen2026-08-05T22:05:12.806283+00:00GABAergic Cells in Zona Incerta: New Insights into MotivationGABAergic cells, zona incerta, motivation modulation, neuroscience, treatment-resistant deficits, brain functionhttps://mindmedicinelaw.com/briefing/patient-perspectives-on-implanted-neurotech-for-depression-20260803-29372The Psychedelic Journalen2026-08-05T22:05:04.618550+00:00Patient Perspectives on Implanted Neurotech for Depressionimplanted neurotechnology, treatment-refractory depression, patient-centered design, neurotechnology adoption, therapy delivery flexibility, implant approach, deep brain stimulation, neurotechnology ethics, patient decision-making, neurotechnology innovationhttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-new-avenues-for-motivation-20260803-29376The Psychedelic Journalen2026-08-05T22:04:55.557335+00:00GABAergic Cells in Zona Incerta: New Avenues for MotivationGABAergic cells, zona incerta, motivation modulation, neuroscience, mental health treatment, treatment-resistant deficitshttps://mindmedicinelaw.com/briefing/distinct-brain-activity-from-psychedelics-in-rat-studies-20260803-29329The Psychedelic Journalen2026-08-05T22:04:28.559639+00:00Distinct Brain Activity from Psychedelics in Rat Studiesserotonergic psychedelics, brain activity patterns, neuropsychiatric disorders, psilocybin, LSD, 2C-B, metabolic activity, therapeutic applications, clinical research, psychedelic therapieshttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-morning-cortisol-new-insights-20260801-29279The Psychedelic Journalen2026-08-06T15:06:38.482258+00:00Ketamine's Impact on Morning Cortisol: New Insightsketamine, cortisol, suicidal thoughts, antidepressant effects, psychedelic research, clinical trials, FDA, neurochemistry, mental health, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/enactive-approach-to-ketamine-therapy-new-insights-20260731-29663The Psychedelic Journalen2026-08-07T15:06:25.282563+00:00Enactive Approach to Ketamine Therapy: New Insightsketamine-assisted psychotherapy, enactivism, psychedelic therapy, transformative potential, clinical research, philosophical framework, adaptive bodies, set and setting, cognitive processes, therapeutic practiceshttps://mindmedicinelaw.com/briefing/ketamine-therapy-for-veterans-expands-in-charlotte-20260729-29278The Psychedelic Journalen2026-08-06T15:06:48.969923+00:00Ketamine Therapy for Veterans Expands in Charlotteketamine therapy, veterans mental health, psychedelic-assisted therapy, Charlotte clinic, PTSD treatment, FDA breakthrough therapy, mental health policy, psychedelic research, healthcare integrationhttps://mindmedicinelaw.com/briefing/neuroimmune-pathways-in-ketamine-and-psychedelics-20260728-29267The Psychedelic Journalen2026-08-05T22:04:38.817309+00:00Neuroimmune Pathways in Ketamine and Psychedelicsneuroimmune signaling, ketamine, psychedelics, rapid antidepressant effects, depression treatment, clinical trials, drug development, mental health, neuroscience, policy implications